FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Pistorius' Brother Facing Own Homicide Trial

The attorney for Oscar Pistorius' family said today that the Olympian's brother is facing a culpable homicide charge relating to a 2008 road accident in which a motorcyclist was killed.

Carl Pistorius, who sat behind his younger brother, Oscar, every day at his bail hearing, will now face his own homicide trial for the accident five years ago, which his attorney, Kenny Oldwage, said he "deeply regrets."

Carl Pistorius is charged with culpable homicide, which refers to the unlawful negligent killing of another person. The charges were initially dropped, but were later reinstated, Oldwage said in a statement.

Full Coverage: Oscar Pistorius Case

Pistorius quietly appeared in court on Thursday, one day before his Paralympic gold-medalist brother was released on bail, Oldwage said. His next appearance is scheduled for the end of March.

Liza van Deventer/Foto24/Gallo Images/Getty Images

'Blade Runner' Murder Charges: Oscar Pistorius Out on Bail Watch Video

Oscar Pistorius Granted Bail in Murder Case Watch Video

It was the latest twist in a case that has drawn international attention, after 26-year-old Oscar Pistorius, a double amputee who ran in both the 2012 Olympic and Paralympic games, was charged with the premeditated murder of his model girlfriend, Reeva Steenkamp.

On Saturday, Carl Pistorius' Twitter handle was hacked, according to a family spokeswoman, prompting the Pistorius family to cancel their social media accounts.

Steenkamp's parents speak about the Valentine's Day shooting that ended their daughter's life in a sit-down interview on South African television tonight.

On Saturday, the model's father, Barry Steenkamp, told the Afrikaans-language Beeld newspaper that Pistorius will have to "live with his conscience" and will "suffer" if his story that he shot Steenkamp because he believed she was an intruder is false.

RELATED: Oscar Pistorius Case: Key Elements to the Murder Investigation

After a four-day long bail hearing, Pistorius was granted bail Friday by a South African magistrate.

The court set bail at about $113,000 (1 million rand) and June 4 as the date for Pistorius' next court appearance.

Pistoriuis is believed to be staying at his uncle's house as he awaits trial. As part of his bail conditions, Pistorius must give up all his guns, he cannot drink alcohol or return to the home where the shooting occurred, and he must check in with a police department twice a week.

Read More..

Egypt's ElBaradei urges election boycott

CAIRO: Opposition leader Mohamed ElBaradei on Saturday called for a boycott of Egypt's upcoming legislative elections, as the president rescheduled the first round after Copts complained it would clash with a Christian holiday.

"Called for parliamentary election boycott in 2010 to expose sham democracy. Today I repeat my call, will not be part of an act of deception," the Nobel Peace laureate and former head of the UN atomic watchdog wrote on Twitter.

Former foreign minister Amr Mussa, another leader in the National Salvation Front (NSF), said many members of the opposition bloc were inclined to boycott the four-round election, but a final position had not yet been taken.

"There is a large group that wants a boycott, but it has not yet been discussed, and no decision has been taken," he told AFP.

Initially the election had been set to begin on April 27, with a new parliament to convene on July 6.

But the dates conflicted with pre-Easter and Easter holidays, prompting Islamist President Mohamed Morsi to announce new ones "in response to requests by Christian brothers," a reference to the Coptic Church, his office said Saturday.

A statement said the new starting date for the election would be April 22-23 instead of 27-28 which fell on the Christian holidays of Lazarus Saturday and Palm Sunday.

The second round will take place on April 29-30 instead of May 4-5, to avoid interference with Easter weekend, the statement said, adding that as a result of the changes parliament was now set to convene on July 2, instead of July 6.

Earlier Father Rafiq Greish, the Catholic Church's spokesman in Egypt, told AFP that he spoke with the presidency, which "accepted" rescheduling the first round.

Many Copts fear that Morsi and his Islamist allies seek to marginalise the minority community which represents six to 10 per cent of Egypt's 83-million population of mostly Sunni Muslims.

ElBaradei, who did not elaborate about his boycott call on Twitter, raised suspicion that the vote might be rigged, as was the case in a 2010 election under ousted long-time president Hosni Mubarak.

Leaders of the NSF, an alliance that brings together liberal and secular leaning groups, have previously proposed a postponement of the vote.

The coalition organised massive protests against Morsi in November and December after he adopted now-repealed powers that shielded his decisions from judicial review.

But anti-Morsi protests have slowed since he pushed through an Islamist-drafted constitution in a December referendum, with the mass rallies giving way to smaller, and often violent, protests.

The opposition, less organised than Morsi's Muslim Brotherhood, has insisted the president appoint a new government before the election while the presidency says the new parliament should have the right to appoint the cabinet.

The Brotherhood and Islamist allies dominated the last parliamentary election in 2011 that resulted in an Islamist-majority house which a court annulled on a technicality before Morsi's election last June.

But due to increased anti-Morsi sentiment, Hamdeen Sabahi, another NSF leader, has said the opposition coalition could now win up to 50 per cent of seats in parliament if it chose to contest the election.

- AFP/jc

Read More..

Hyderabad blasts: Local outfit under police’s scanner

HYDERABAD: With no breakthrough so far in Dilsukhnagar serial blasts that claimed 17 lives and left nearly 150 injured, the investigating agencies are scanning the activities of Dursgah-e-Jihad-o-Shahadat (DJS), a city-based outfit whose members were alleged to have been involved in a series of terror attacks in the past.

"DJS has been a training ground for militants in the past. Many of them had developed links with foreign intelligence agencies and terrorist organisations and carried out attacks in Hyderabad and elsewhere. It is critical to know the status of these members in the context of the latest blasts," a police officer said on condition of anonymity.

Local police sources said the outfit lost its sheen after the death of its founder Shaikh Mahboob Ali in 2011. The new DJS president Mohammed Abdul Majid, son-in-law of the founder, staged a protest on December 6, the anniversary of Babri Masjid demolition. He also organised protests against a police officer in October for which he was behind bars for over two weeks.

Police sources said IM operative Syed Maqbool, who was arrested by the Delhi police in October last year for planning terror attacks across the country, was once linked to DJS. Mohammed Abdul Shahid Bilal and his brother Samad, who were first linked with Mecca Masjid bomb blast and later killed in Karachi, were also DJS members. Mohammed Viquar, who reportedly killed two policemen in 2009 and 2010 had his initial training with DJS. Another militant Ghulam Yazdani, who was killed in a police encounter in Delhi, also owed allegiance to the outfit.

The founder's grandson Nijihullah was packed off to Saudi Arabia to escape police, but later fell into the hands of Pakistani terror handlers. He was reportedly trained in Pakistan and later pushed back into India. His present whereabouts are not known.

Denying any role in terror activities, DJS President Abdul Majid had earlier claimed that the outfit had trained about 50,000 youths in self-defence in the past. The two camps of DJS where "self-defence training" was imparted—Ujale Shah Eidgah grounds and Purani Haveli—are now defunct.

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Pistorius Family: 'Law Must Run Its Course'

South African Olympian Oscar Pistorius is spending time his family today after the athlete was freed on $113,000 bail Friday.

"We realise that the law must run its course, and we would not have it any other way," the Olympian's uncle, Arnold Pistorius said in a statement on Saturday.

The Pistorius family expressed their gratitude that the former Olympian was allowed out of jail before the trial.

"This constitutes a moment of relief under these otherwise very grave circumstances" said Arnold Pistorius."We are extremely thankful that Oscar is now home."

Pistorius, 26, is charged with premeditated murder in the Valentine's Day shooting of his girlfriend Reeva Steenkamp.

While the prosecution argued that the world-renowned athlete was a flight risk and had a history of violence, South African Magistrate Desmond Nair, who presided over the case, disagreed.

FULL COVERAGE: Oscar Pistorius

"He regards South Africa as his permanent place of abode, he has no intention to relocate to any other country" Nair said during his two hour ruling, before concluding with, "the accused has made the case to be released on bail."

'Blade Runner' Murder Charges: Oscar Pistorius Out on Bail Watch Video

Oscar Pistorius Granted Bail in Murder Case Watch Video

Pistoriuis will have to adhere to strict conditions to stay out of jail before the trial. He must give up all his guns, he cannot drink alcohol or return to the home where the shooting occurred, and he must check in with a police department twice a week.

Oscar Pistorius is believed to be staying at an uncle's house as he awaits trial.

RELATED: Oscar Pistorius Case: Key Elements to the Murder Investigation

During the hearing, the prosecution argued that Pistorius shot Steenkamp after an argument, while the defense laid out an alternate version of events saying Pistorius mistook his girlfriend for an intruder.

Nair took issue with the head detective originally in charge of the case, who he said "blundered" in gathering evidence and was removed from the case after it was revealed he is facing attempted murder charges.

RELATED: Oscar Pistorius Case: Lead Det. Hilton Botha to Be Booted From Investigation Team

After the magistrate's decision, cheers erupted in the courtroom from the Pistorius camp. Pistorius' trial is expected to start in six to eight months, with his next pre-trial court date in June.

Reeva Steenkamp Family Reaction

Steenkamp's father, Barry Steenkamp told the South African Beeld newspaper that the 26-year-old athlete will "suffer" if he is lying about accidentally shooting 29-year-old model.

PHOTOS: Oscar Pistorius Charged with Murder

Barry Steenkamp went on to say that the Pistorius will have to "live with his conscience" if he intentionally shot Reeva.

The Associated Press contributed to this report.

Read More..

Abe: Japan acting calmly in island dispute with China

WASHINGTON (Reuters) - Japanese Prime Minister Shinzo Abe on Friday said he told President Barack Obama in a meeting that Japan would act calmly in its row with China over tiny islands in the East China Sea claimed by both Asian countries.

"I explained that we have always been dealing with this issue ... in a calm manner," he said through a translator, while sitting next to Obama in the White House Oval Office.

"We will continue to do so and we have always done so," he said.

Tension has raised fears of an unintended military incident near the islands, known as the Senkaku in Japan and the Diaoyu in China. Washington says the islets fall under a U.S.-Japan security pact, but it is eager to avoid a clash in the region.

Abe said the existence of the Japan-U.S. alliance was a stabilizing factor in the area.

"We agreed that we would stay in close coordination with each other in dealing with such issues and other issues," he said.

Obama, in his remarks to reporters, said Japan was one of the United States' closest allies. He said the two men would discuss trade and other economic issues and agreed that their top priority was economic growth.

Obama declined to answer a reporter's question on whether they would discuss the Japanese yen.

Expectations for Abe's economic programs, especially monetary easing, have cut some 10 percent off the yen's value against the U.S. dollar since Abe took office, raising concern that Japan is weakening its currency to export its way out of recession.

Obama and Abe also discussed North Korea and agreed to cooperate at the United Nations over the issue. Abe said the two men also talked about additional sanctions against North Korea, which tested a nuclear bomb last week in defiance of U.N. resolutions.

(Editing by Vicki Allen)

Read More..

US sequester cuts will force major flight delays

WASHINGTON: US Transportation Secretary Ray LaHood said Friday that looming automatic budget cuts will force air traffic control cutbacks and cause flight delays in major cities by up to 90 minutes.

LaHood said the US$85 billion "sequester" cuts scheduled for March 1 will compel the Federal Aviation Administration to reduce airport staffing around the country, shutting towers at smaller airports and causing a general slowdown of civil aviation operations.

"Sequester will have a very serious impact on the transportation services that are critical to the traveling public and to the nation's economy," LaHood told reporters at the White House.

At the department of transportation, he said, spending will be reduced by nearly US$1 billion, including US$600 million at the FAA for the March-September period.

That means the FAA will furlough -- mandate unpaid leave -- most of its 47,000 workers for between two and four days each month beginning in April, LaHood said.

That will mean less air traffic control services at large and small airports around the country, likely forcing flight schedule changes and slowdowns by airlines.

"Once airlines see the potential impact of these furloughs, we expect that they will change their schedules and cancel flights."

"Obviously, as always, safety is our top priority, and we will never allow the amount of air travel we can handle safely to take off and land -- which means travellers should expect delays," LaHood warned.

In a letter to airline and airport managers around the country, LaHood said the cutbacks will mean the elimination of midnight shifts in 30 secondary airports like El Paso, Texas and Chicago's Midway, and the closure of traffic control towers at 100 smaller airports.

The FAA will have to reduce equipment maintenance and support as well.

As a consequence, "travellers should expect delays," he said in the letter.

"Flights to major cities like New York, Chicago and San Francisco could experience delays of up to 90 minutes during peak hours because we will have fewer controllers on staff."

The sequester -- harsh automatic spending cuts over 10 years agreed in a 2011 political deal to force deficit reduction -- will take effect on March 1 if Democrats and Republicans cannot compromise on a less austere program before then.

President Barack Obama wants to replace the cuts with a balanced set of spending cuts and revenue hikes obtained by closing tax loopholes, but Republicans in Congress are resisting the idea of higher taxes.

- AFP/jc

Read More..

Indian Mujahideen shows yet again that it is alive and kicking

NEW DELHI: Indian Mujahideen, Pakistani terror outfit Lashkar-e-Taiba's proxy in India, may have been down after the August 2012 Pune serial blasts but it's certainly not out as it has the capacity to regroup after every clampdown. The Hyderabad incident has once again proved that the banned group is not only alive but also kicking through its potent sleeper cells in different states.

Getting continuous support from the Pakistani spy agency ISI, the outfit has enough resources to make its presence felt at regular intervals through attacks in different cities. Its supply lines of explosives, detonators and micro chips are intact and it can attack anywhere in the country with as much ease as it did during its peak in 2007-08 when it carried out blasts in Lucknow, Faizabad, Varanasi, Jaipur, Ahmedabad and Delhi.

A Delhi Police dossier, prepared after last year's Pune blasts and shared with the home ministry in September, shows that the terror outfit has modules in Andhra Pradesh, Uttar Pradesh, Madhya Pradesh, Bihar, Gujarat, Maharashtra, Karnataka, Kerala and Delhi where it recruited cadre during the lull of 2009. It came to action again in 2010 when it attacked German Bakery in Pune and carried out a shootout and blast outside Jama Masjid in Delhi.

The dossier, shared with all states, says the IM's top leaders - Amir Raza Khan and Bhatkal brothers (Iqbal and Riyaz) - are currently in Pakistan while others have safe hideouts in Saudi Arabia, Nepal and the UAE (Dubai and Sharjah). Khan and the Bhatkal brothers were among the founding members of the outfit which later took in its fold almost all the cadres of Students Islamic Movement of India (SIMI).

The dossier says that IM - which was set up by ISI to camouflage its own footprint and project to the world that Islamic terrorism in India was indigenous in character and content - has "substantial corpus of money", having funding sources based in Kuwait, Riyadh, Chicago and different cities in Pakistan.

Even though a number of operatives were arrested in 2011-12 by Delhi, Maharashtra and Gujarat police, 15 key absconders - Yasin Bhatkal, Shahnawaz, Abu Rashid, Abdus Subham Qureshi, Tehsin and Mirza Shadab Bai among them - have been carrying out operations under the guidance of their bosses in Pakistan.

Calling IM a "start to finish jihad factory", the dossier highlighted that "innocuous religious platforms" like Quran Foundation, Pune and Islamic Guidance Centre, Mangalore were among institutions from where foot soldiers were recruited, which included disenchanted Muslim youth ranging from petty criminals to highly paid software professionals. It noted how the outfit had recruited its prized operative -- Mansoor Ali Mohammed Peerbhoy -- while he was studying Arabic at the Quran Foundation.

Peerbhoy, a Yahoo techie-turned-media chief of the terror outfit who was arrested in 2008, had brought in a number of educated youth to the IM's fold. Recruitments of Arif Badar, IED assembly and micro chip-based timer expert, and Mobin, internet hacking expert, were testimony of how talented ones were identified and trained as terrorists through fiery and emotive 'taqrirs' (speech) and attitude hardening 'dars' (lessons).

It was noted that "brainwashing through doctored pictorials and videos, such as that of Godhra and Babri Masjid incidents" was very common in these 'taqrirs' and 'dars'.

Use of 'social networking sites' for sending personalized messages and motivating vulnerable youth had also come to the notice of investigating agencies, prompting them to suggest setting up "massive and sophisticated surveillance infrastructure" in the country.

Though the IM came to notice for the first time when it sent emails to media houses before the serial blasts in Faizabad, Lucknow and Varanasi in Uttar Pradesh in November 2007, its genesis - the dossier says - goes back to the year 2000 when the underworld network was roped in to organize talent spotting, motivation and training of Indian youth at the facilities of LeT and ISI.

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..